2026 Pyruvate carboxylase deficiency strategy: epidemiology, PC biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Pyruvate dehydrogenase deficiency strategy: epidemiology, PDHA1 biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Mitochondrial encephalomyopathy strategy: epidemiology, POLG biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Glutaric acidemia type II strategy: epidemiology, ETFDH biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Nonketotic hyperglycinemia strategy: epidemiology, GLDC biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Hyperornithinemia-hyperammonemia-homocitrullinuria syndrome strategy: epidemiology, SLC25A15 biology, clinical competition, recent deals, unmet need and…

2026 Argininosuccinic aciduria strategy: epidemiology, ASL biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Hereditary fructose intolerance strategy: epidemiology, ALDOB biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Galactosemia strategy: epidemiology, GALT biology, clinical competition, recent deals, unmet need and market attractiveness. Evidence synthesized with…

2026 Premenstrual dysphoric disorder strategy: epidemiology, GABA-A receptor biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Persistent depressive disorder strategy: epidemiology, SERT biology, clinical competition, recent deals, unmet need and market attractiveness.

2026 Treatment-resistant schizophrenia strategy: epidemiology, M1 receptor biology, clinical competition, recent deals, unmet need and market attractiveness.